Tenax Therapeutics, Inc. has finalized a Supply Agreement with Orion Corporation, designating Orion as the primary supplier for Tenax's orally administered levosimendan product. This agreement covers manufacturing and supply, including provisions for forecasting, ordering, delivery, quality, pricing, and alternative manufacturing rights. Cost-sharing for scaling up Orion's manufacturing capabilities is also included. The Supply Agreement has an initial term of five years from the first delivery, with automatic three-year renewals unless 24 months' notice is given. A Sixth Amendment to the existing License Agreement between Tenax and Orion has also been executed. This amendment extends the deadline for obtaining regulatory approval for the product in the United States to December 31, 2035. The amendment also requires Tenax to comply with Orion's information and cybersecurity requirements.